Study
| Randomised, open-label, phase 3 study (KEYNOTE-177) |
| Untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer |
| Pembrolizumab 200 mg every 3 weeks (N:153) or to the investigator’s choice (N:154) |
Efficacy
| mOS: NR vs 36·7 months [HR:0·74; 0·53–1·03; p=0·036] |
| mPFS: 16·5 vs 8·2 months [HR 0·59, 95% CI 0·45–0·79] |
Safety
| Grade >= 3 AEs: 22% vs 66% |
| Grade >= 3 AEs for pembrolizumab: increased ALT (2%), colitis (2%), diarrhoea (2%), and fatigue (2%) |
| Grade >= 3 AEs for chemotherapy: neutropenia (15%), diarrhoea ( 10%), fatigue (9%) |
Lancet Oncol. 2022 May;23(5):659-670
http://doi.org/10.1016/s1470-2045(22)00197-8
Reviewed by Hasan Cagri Yildirim, MD on Jul 16, 2022
